April 2, 2012 1:51 PM EDT Wedbush reiterates an 'Outperform' on AVI BioPharma (NASDAQ: AVII) price target of $2.50.
Analyst, Gregory R. Wade, said, "AVII reported top-line results from its Phase IIb trial of eteplirsen in boys with Duchenne muscular dystrophy (DMD). Patients receiving the 30 mg/kg dose over 24 weeks met the primary endpoint of increasing levels of dystrophinpositive fibers by a mean 22.5%, the largest effect seen to date with eteplirsen. The higher dose of 50 mg/kg did not show a statistically significant protein response, but recall that it was dosed only over 12 weeks, supporting long-term eteplirsen dosing."
Wade also noted some confusion in clinical stats and shares having significantly declined, but Wade is confident in significantly increased dystrophin levels at 24 wks with the 30 mg/kg dose as likely to lead to improved clinical outcomes.